Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer is the most common subtype, accounting for approximately 75% of breast cancers and 70% of metastatic breast cancer (MBC) cases (Huang et al., 2022). Here, ERBB2 is linked to breast carcinoma.